CTOs on the Move

Target RWE Health Evidence Solutions

www.targetrwe.com

 
At Target RWE, we are redefining and revolutionizing the generation and delivery of real-world evidence. Contact us today!
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Karius

Karius is a life sciences company focused on generating genomic insights for infectious diseases with a non-invasive blood test that helps clinicians make rapid treatment decisions. By mapping each patient`s microbial landscape from a single blood draw, Karius moves closer to a vision of a world where infectious disease is no longer a major threat to human health.

NanoLogix

NanoLogix is a biotechnology company specializing in live cell, rapid diagnostics. Our kits are simple and reliable rapid test solutions that detect active threat bacteria and other microorganisms 4x - 12x faster than traditional Petri culture technology, and more cost effectively than PCR Protocol.   NanoLogix FlatPack packaging allows for an extended shelf-life that is frequently more than double today's standard. In ongoing shelf-life tests, NanoLogix plates containing TSA media in FlatPacks have maintained nutrient and moisture levels for over two years in cold storage and over one year at room temperature (RT). Other agars have their usable shelf lives extended by varying amounts. NanoLogix plates can be used for isolating microorganisms, total plate count, and for maintaining stock cultures.

Limelight Bio

Limelight is a privately held, multi-platform, multi-disease biopharmaceutical company headquartered in Philadelphia, PA and Cambridge, MA

Odonate

Odonate Therapeutics™ is dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Our initial focus is on the development of tesetaxel, an investigational, orally administered taxane. We are conducting our multinational, multicenter, randomized, Phase 3 study in locally advanced or metastatic breast cancer (MBC), known as CONTESSA. Our goal is to develop an effective chemotherapy choice for patients that provides quality-of-life advantages over current alternatives.

Juno Therapeutics

Juno Therapeutics is building a fully integrated biopharmaceutical company focused on revolutionizing medicine by re-engaging the body`s immune system to treat cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as solid tumors. Several product candidates have shown compelling evidence of tumor shrinkage in clinical trials in refractory leukemia and lymphoma conducted to date. Juno`s long-term aim is to leverage its cell-based platform to develop new product candidates that address a broader range of cancers and human diseases. Juno brings together innovative technologies from some of the world`s leading research institutions, including the Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, Seattle Children`s Research Institute, and The National Cancer Institute. Juno Therapeutics has an exclusive license to the St. Jude Children`s Research Hospital patented technology for CD19 directed product candidates that use 4-1BB, which was developed by Dario Campana, Chihaya Imai, and St. Jude Children`s Research Hospital.